Details of the Drug

General Information of Drug (ID: DMM9BJD)

• Drug Name: Tisagenlecleucel
• Synonyms: Tisagenlecleucel-T

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Approved	[1]
Chronic lymphocytic leukaemia	2A82.0	Phase 3	[2]
Diffuse large B-cell lymphoma	2A81	Phase 3	[2]
Follicular lymphoma	2A80	Phase 2	[2]
Acute myeloid leukaemia	2A60	Application submitted	[3]

• Drug Type: CAR T Cell Therapy
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 9.91 days []
  Half-life: The concentration or amount of drug in body reduced by one-half in 16.8 days []
• Cross-matching ID:
  DrugBank ID: DB13881
  TTD ID: D0IM6T
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	Immunostimulant	[1]
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Immunostimulant	[3]

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)